Drugs / ATYR1940
ATYR1940
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02836418 | Jul 2016 → Apr 2017 | facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy | aTyr Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02603562 | Mar → Dec 2016 | facioscapulohumeral muscular dystrophy | aTyr Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02579239 | Nov 2015 → Oct 2016 | facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy | aTyr Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02531217 | Aug 2015 → May 2016 | facioscapulohumeral muscular dystrophy | aTyr Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02239224 | Sep 2014 → Dec 2015 | facioscapulohumeral muscular dystrophy | aTyr Pharma, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2018-05-02 | aTyr Pharma, Inc. | Results aTyr Pharma Provides Mechanistic Update on Resokine Pathway at American Academy of Immunology Annual Meeting atyrpharma.com ↗
Conclusions: ATYR1940 reduced human T cell activation as indicated by lower surface expression of activation markers and decreased release of Th1, Th2, and Th17 cytokines. |
| 2017-09-27 | aTyr Pharma, Inc. | Results aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society atyrpharma.com ↗
In this exploratory, open-label study, Resolaris was generally well tolerated at doses up to 3.0 mg/kg once weekly in patients aged 16 to 20 years with early-onset FSHD. |
| 2017-04-24 | aTyr Pharma, Inc. | Results aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting atyrpharma.com ↗
Data from all clinical trials completed to date demonstrate that Resolaris has a favorable safety profile and was generally well-tolerated across all doses tested. |
| 2016-10-06 | aTyr Pharma, Inc. | Results aTyr Pharma Presents Additional Data for Resolaris™ Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral Muscular Dystrophy at the 21st International Annual Congress of the World Muscle Society atyrpharma.com ↗
aTyr Pharma, Inc. (Nasdaq: LIFE), today announced that additional clinical data from aTyr's Phase 1b/2 Trial (002) in adult patients with FSHD were presented at the 21st International Congress of the World Muscle Society in Granada, Spain. |
All press releases naming this drug 15 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATYR1940 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02531217 ↗ |
| Known as | Hars (residues 2-506) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297550 ↗ |
| Known as | Resolaris | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297550 ↗ |
| Route | Intravenous | “ATYR1940 0.3 milligrams/kilograms (mg/kg) intravenous (IV) infusion” NCT02239224 ↗ |